| Literature DB >> 35821038 |
Tatiana T Marquez-Lago1, Stanly Steinberg2.
Abstract
Progesterone receptor (PR) transcriptional activity is a key factor in the differentiation of the uterine endometrium. By consequence, progestin has been identified as an important treatment modality for endometrial cancer. PR transcriptional activity is controlled by extracellular-signal-regulated kinase (ERK) mediated phosphorylation, downstream of growth factor receptors such as EGFR. However, phosphorylation of PR also targets it for ubiquitination and destruction in the proteasome. Quantitative studies of these opposing roles are much needed toward validation of potential new progestin-based therapeutics. In this work, we propose a spatial stochastic model to study the effects of the opposing roles for PR phosphorylation on the levels of active transcription factor. Our numerical simulations confirm earlier in vitro experiments in endometrial cancer cell lines, identifying clustering as a mechanism that amplifies the ability of progesterone receptors to influence gene transcription. We additionally show the usefulness of a statistical method we developed to quantify and control variations in stochastic simulations in general biochemical systems, assisting modelers in defining minimal but meaningful numbers of simulations while guaranteeing outputs remain within a pre-defined confidence level.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35821038 PMCID: PMC9276744 DOI: 10.1038/s41598-022-13821-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Concentrations of molecular species, diffusion, and reaction rates.
| Parameter | Value | References |
|---|---|---|
| EGFR | 50,000–100,000 per cell | Measured experimentally and[ |
| ERK | 50,000–100,000 per cell | [ |
| Progesterone (p4) | 10−9–10−6 molar, and we used a molarity of 10–7 for all simulations | [ |
| Progesterone receptors | 10,000–12,000 per cell | [ |
| Ubiquitin | In excess (not rate limiting) | [ |
| Diffusion inside cytoplasm | 10−8 cm2/s | [ |
| Diffusion inside nucleus | 10–9 cm2/s | [ |
| k1 | 1 | Flexible[ |
| ki, ‘i’ ≠ 1, 2, 4, 6, 7 | 1010 | [ |
Dimensions and volumes for cellular compartments.
| Method | Cell dimensions/diameter ( | Cell volume ( | Nuclear dimensions/diameter ( | Nuclear volume ( | N |
|---|---|---|---|---|---|
| Cell counter | 17.7 ± 2.1 | 2900 | – | – | 1930 |
| Electron microscopy | 18.2 ± 3.4 | 3130 | 11.2 | 727 | 4 |
| Confocal microscopy | 19 | 3611 | 12.8 | 1100 | 11 |
| Histology | 22.2 × 11.8 × 11.8 | 3100 | 17.9 × 9.6 × 9.6 | 870 | 2027 |
Figure 1Morphometric analysis of electron micrographs taken of ultra-thin sections of Hec50co endometrial cells. Volumes for each simulation cellular compartment (cytoplasm, nucleus) were determined from estimations of suspended Hec50co cells.
Figure 2Illustration of the model summarizing key aspects of progesterone receptor regulation. Approximately 50% of PRB is cytoplasmic in the absence of progesterone, while PRA is considered to be 100% resident in the nucleus whether or not ligand is present[8]. Two ligand binding steps are required to maximally support PRB shuttling into the nucleus where it can form active dimerized transcription factor. In one step, growth factors bind to surface receptors, such as the EGFR, leading to the activation of the MAP kinase family members, ERK1 and ERK2. Activated ERK phosphorylates PRB. Cytosolic, phosphorylated PRB binds progesterone and translocate to the nucleus[6]. Ligand binding at this stage is not rate-limiting. On one hand, ligand binding is a relatively fast event (compared to the expected time for PR translocation). On the other, growth factors may bypass ligand activation by inducing rapid translocation to the nucleus, with ligand concentrations that are normally too low to stimulate activation without other stimuli[4]. PRA is also a substrate for ERK phosphorylation, once active MAP kinase translocates to the nucleus. Nuclear, ligand-bound progesterone receptors form hetero- and homodimers and, in endometrial tissue, stimulate transcription of genes that mediate differentiation and growth arrest. PRA and PRB are also substrates for ubiquitination, targeting receptors for translocation to the cytosol and proteosomal degradation.
Reactions considered in all models (‘sc’ indicates scenario).
| Reaction | Region | Notes | Model |
|---|---|---|---|
| Cytoplasm | Lump phosphorylation, following model in[ | 1, sc 1 | |
| Cytoplasm | Nuclear translocation (~ 5 min) | 1, sc 1 | |
| Cytoplasm | PRB phosphorylation | 1, sc 1 | |
| Cytoplasm | Nuclear translocation, (~ 5 min) | 1, sc 1 | |
| Cytoplasm | Ligand bound PRB | 1, sc 2 | |
| Cytoplasm | Nuclear translocation, (~ 30 min) | 1, sc 2 | |
| Nucleus | ERK translocation for activation (~ 20 min) | 1, sc 1 | |
| Nucleus | PRA phosphorylation | 2, sc 1 | |
| Nucleus | pPRB binding to ligand | 2, sc 1 | |
| Nucleus | pPRA binding to ligand | 2, sc 1 | |
| Nucleus | PRB binding to ligand | 2, both | |
| Nucleus | PRA binding to ligand | 2, both | |
| Nucleus | TFAA formation | 2, both | |
| Nucleus | TFAB formation | 2, both | |
| Nucleus | TFBB formation | 2, both | |
| Nucleus | TFAA formation | 2, sc 1 | |
| Nucleus | TFAB formation | 2, sc 1 | |
| Nucleus | TFBB formation | 2, sc 1 | |
| Nucleus | TFAA formation | 2, sc 1 | |
| Nucleus | TFAB formation | 2, sc 1 | |
| Nucleus | TFAB formation | 2, sc 1 | |
| Nucleus | TFBB formation | 2, sc 1 | |
| Nucleus | pPRB (or bpPRB) ubiquitination | 2, sc 1 | |
| Nucleus | pPRA (or bpPRA) ubiquitination | 2, sc 1 |
Reactions and rates considered in the transcription model.
| Reaction | Region | Notes |
|---|---|---|
| Lumped | Lumped ERK activation | |
| Nucleus | Ligand bound PRA | |
| Nucleus | Ligand bound PRB | |
| Nucleus | PRA activation | |
| Nucleus | PRB activation | |
| Nucleus | TFAA formation | |
| Nucleus | TFAB formation | |
| Nucleus | TFBB formation | |
| Nucleus | TFAA binding to DNA | |
| Nucleus | TFAB binding to DNA | |
| Nucleus | TFBB binding to DNA | |
| Nucleus | Lumped transcription, mRNA initiation | |
| Nucleus | Lumped transcription, mRNA initiation | |
| Nucleus | Lumped transcription, mRNA initiation | |
| Nucleus | DNA site again available for binding | |
| Nucleus | TFAA ubiquitination | |
| Nucleus | TFAB ubiquitination | |
| Nucleus | TFBB ubiquitination | |
| Nucleus | TFAA ubiquitination | |
| Nucleus | TFAB ubiquitination | |
| Nucleus | TFBB ubiquitination | |
| Nucleus | mRNA elongation | |
| Nucleus | Final mRNA |